vaccine, meningococcal


Sanofi Pasteur


Zuellig Pharma
Concise Prescribing Info
Meningococcal (groups A, C, Y & W-135) polysaccharide diphtheria toxoid conjugate vaccine
Active immunization of individuals 9 mth to 55 yr for the prevention of invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y & W-135.
Dosage/Direction for Use
0.5 mL as single IM dose preferably in the anterolateral thigh or deltoid region. Childn 9-23 mth 2-dose series at least 3 mth apart. Individuals 2-55 yr Given as a single dose. Booster vaccination Individuals 15-55 yr Single booster dose if at least 4 yr have elapsed since the prior dose.
Hypersensitivity. Moderate or severe febrile or acute disease.
Special Precautions
Do not administer IV or SC. Guillain-Barré syndrome. Patients w/ possible vaccine sensitivity & previous vaccination-related adverse reactions, thrombocytopenia or bleeding disorders. Immunosuppressed patients. Pregnancy & lactation. Infant <9 mth. Elderly >55 yr.
Adverse Reactions
Inj site reactions (pain, tenderness, redness & swelling), irritability, diarrhea, drowsiness, anorexia, headache, fatigue; myalgia; fever ≥40°C & seizures.
Drug Interactions
Immunosuppressive therapies including irradiation, antimetabolites, alkylating agents, cytotoxic drugs & corticosteroids may reduce the immune response to vaccines.
ATC Classification
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Menactra vaccine (inj) 0.5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in